Objective To analyze the effects of erector spinae plane block(ESPB)on postoperative analgesic consumption,visual analog scale(VAS)pain scores,and postoperative nausea and vomiting(PONV)in breast cancer patients,and to evaluate its advantages and disadvantages compared to general anesthesia(GA),thoracic paravertebral block(TPVB),and pectoral nerve block(PECS),providing a systematic review of its clinical application.Methods We searched English databases including PubMed,Embase,Scopus,Cochrane Library,and Web of Science,as well as Chinese databases such as CNKI,Wanfang,and Weipu,including randomized controlled trials.The Cochrane bias risk assessment tool was used for bias risk evaluation,and RevMan 3.5 software was utilized for meta-analysis.Results A total of 31 randomized controlled trials involving 2296 patients were included.The meta-analysis results indicated that the morphine consumption in the ESPB group was lower than that in the GA group at 24 hours postoperative(MD-17.57,95％CI-23.99 to-11.14,P＜0.05).VAS scores at 2,6,12,and 24 hours postoperative were also lower in the ESPB group compared to the GA group(P＜0.05),and the incidence of PONV in patients was reduced(RR 0.57,95％CI 0.47 to 0.69,P＜0.05),with all differences being statistically significant.No statistically significant differences were found in morphine consumption at 24 hours postoperative between the ESPB and TPVB groups,nor in VAS scores at 2,12,and 24 hours postoperative,and the number of PONV cases showed no statistically significant difference.The morphine consumption in the PECS group at 24 hours postoperative was lower than that in the ESPB group(MD 10.94,95％CI 4.40 to 17.48,P＜0.05),and the VAS score at 12 hours postoperative in the PECS group was lower than that in the ESPB group(MD 0.59,95％CI 0.19 to 0.99,P＜0.05),indicating statistical significance,while no significant differences were observed at other time points.Conclusions The analgesic effect of the ESPB group is superior to that of the GA group and similar to that of the TPVB group,but inferior to that of the PECS group.Compared to the GA group,ESPB significantly reduces the incidence of postoperative PONV,showing similarity with the TPVB and PECS groups.

Objective To explore the mechanism of high mobility group AT-hook 1(Hmga1)in regulating the osteogenic differentiation of bone marrow mesenchymal stem cell(BMSC)through the Wnt/β-catenin pathway in the treatment of osteopo-rosis.Methods Hmga1-overexpressing lentiviral vector(LV)was constructed in vitro to transfect rat BMSC,and the Wnt signal inhibitor Dickkopf-1(DKK1)was used for intervention.Osteogenic differentiation-related indices were analyzed by qRT-PCR,Western blot,alkaline phosphatase(ALP)activity detection and Alizarin red staining.Ovariectomized(OVX)osteoporosis rat model was established,and Hmga1-LV was injected into the bone marrow cavity.Micro-CT,histological staining and immuno-fluorescence techniques were used to evaluate the bone microstructure and the expression of osteogenic differentiation-related proteins.Results Hmga1 expression was upregulated in a time-dependent manner during osteogenic differentiation of BMSC,while Hmga1 expression was significantly decreased in the bone tissue of OVX rats.Overexpression of Hmga1 significantly en-hanced the ALP activity and mineralized nodule formation of BMSC,and upregulated the expression of Runt-related transcrip-tion factor 2(Runx2)and osteocalcin(Ocn).The effect was partially reversed by DKK1.Hmga1 overexpression activated the Wnt/β-catenin pathway by promoting the nuclear translocation of β-catenin.In vivo experiments showed that Hmga1-LV treat-ment significantly improved trabecular thickness(Tb.Th)and bone volume fraction(BV/TV)in OVX rats,and reduced trabecu-lar separation(Tb.Sp),but had no significant effect on osteoclast differentiation.Conclusion Hmga1 promotes BMSC osteogen-ic differentiation and reverses OVX-induced bone loss by activating the Wnt/β-catenin signaling pathway,providing a potential target for gene therapy of postmenopausal osteoporosis.

Objective To explore the mechanism of Cistanche phenylethanoid glycosides(CPhGs)in treating osteoporosis by regu-lating osteogenic differentiation via SIRT2-C/EBPβ-AREG axis.Methods An osteoporosis mouse model was established using ova-riectomy.Trabecular number/thickness,bone formation rate,and tissue morphology were evaluated using micro-computed tomography,calcein double labeling,and hematoxylin and eosin staining,respectively.SIRT2,C/EBPβ,AREG,proteins related to the SIRT2-C/EBPβ-AREG axis,were analyzed by Western blotting and co-immunoprecipitation.The mRNA expression of osteogenic differentiation marker genes OCN,OPN,RUNX2,C/EBPβ,and AREG were detected by real-time quantitative PCR.Results CPhGs intervention significantly improved the trabecular microarchitecture and promoted bone formation in mice undergoing ovariectomy,and the mechanism involved the activation of SIRT2-mediated deacetylation of C/EBPβ,which in turn upregulated AREG expression.Cell experiments confirmed that CPhGs significantly increased the activity of alkaline phosphatase and the expression of osteogenic genes such as OCN,OPN,and RUNX2 in MC3T3-E1 cells by enhancing the interaction between SIRT2 and C/EBPβ.Notably,this effect could be reversed by SIRT2 knockdown.Conclusion CPhGs regulate the osteogenic differentiation process through the SIRT2-C/EBPβ-AREG axis,providing a new molecular target and theoretical basis for the treatment of osteoporosis with the active ingredients of traditional Chinese medicine.

Objective To explore the mechanism of Cistanche phenylethanoid glycosides(CPhGs)in treating osteoporosis by regu-lating osteogenic differentiation via SIRT2-C/EBPβ-AREG axis.Methods An osteoporosis mouse model was established using ova-riectomy.Trabecular number/thickness,bone formation rate,and tissue morphology were evaluated using micro-computed tomography,calcein double labeling,and hematoxylin and eosin staining,respectively.SIRT2,C/EBPβ,AREG,proteins related to the SIRT2-C/EBPβ-AREG axis,were analyzed by Western blotting and co-immunoprecipitation.The mRNA expression of osteogenic differentiation marker genes OCN,OPN,RUNX2,C/EBPβ,and AREG were detected by real-time quantitative PCR.Results CPhGs intervention significantly improved the trabecular microarchitecture and promoted bone formation in mice undergoing ovariectomy,and the mechanism involved the activation of SIRT2-mediated deacetylation of C/EBPβ,which in turn upregulated AREG expression.Cell experiments confirmed that CPhGs significantly increased the activity of alkaline phosphatase and the expression of osteogenic genes such as OCN,OPN,and RUNX2 in MC3T3-E1 cells by enhancing the interaction between SIRT2 and C/EBPβ.Notably,this effect could be reversed by SIRT2 knockdown.Conclusion CPhGs regulate the osteogenic differentiation process through the SIRT2-C/EBPβ-AREG axis,providing a new molecular target and theoretical basis for the treatment of osteoporosis with the active ingredients of traditional Chinese medicine.

Objective To explore the mechanism of high mobility group AT-hook 1(Hmga1)in regulating the osteogenic differentiation of bone marrow mesenchymal stem cell(BMSC)through the Wnt/β-catenin pathway in the treatment of osteopo-rosis.Methods Hmga1-overexpressing lentiviral vector(LV)was constructed in vitro to transfect rat BMSC,and the Wnt signal inhibitor Dickkopf-1(DKK1)was used for intervention.Osteogenic differentiation-related indices were analyzed by qRT-PCR,Western blot,alkaline phosphatase(ALP)activity detection and Alizarin red staining.Ovariectomized(OVX)osteoporosis rat model was established,and Hmga1-LV was injected into the bone marrow cavity.Micro-CT,histological staining and immuno-fluorescence techniques were used to evaluate the bone microstructure and the expression of osteogenic differentiation-related proteins.Results Hmga1 expression was upregulated in a time-dependent manner during osteogenic differentiation of BMSC,while Hmga1 expression was significantly decreased in the bone tissue of OVX rats.Overexpression of Hmga1 significantly en-hanced the ALP activity and mineralized nodule formation of BMSC,and upregulated the expression of Runt-related transcrip-tion factor 2(Runx2)and osteocalcin(Ocn).The effect was partially reversed by DKK1.Hmga1 overexpression activated the Wnt/β-catenin pathway by promoting the nuclear translocation of β-catenin.In vivo experiments showed that Hmga1-LV treat-ment significantly improved trabecular thickness(Tb.Th)and bone volume fraction(BV/TV)in OVX rats,and reduced trabecu-lar separation(Tb.Sp),but had no significant effect on osteoclast differentiation.Conclusion Hmga1 promotes BMSC osteogen-ic differentiation and reverses OVX-induced bone loss by activating the Wnt/β-catenin signaling pathway,providing a potential target for gene therapy of postmenopausal osteoporosis.

Three-dimensional (3D) printing, also known as additive manufacturing, is a fabrication technology that constructs three-dimensional objects by successive addition of materials. In recent years, the advancements in 3D printing technology, reductions in material costs, development of biomaterials, and improvements in cell culture techniques allow the application of 3D printing in the clinical medical fields, such as orthopedics, dentistry, and urinary surgery, to develop rapidly. Obstetrics, focusing on both theory and practice, is an emerging application field for 3D printing technology. 3D printing has been used in obstetrics for fetal and maternal diseases, such as prenatal diagnosis of fetal abnormalities and preoperative planning for placental implantation disorders. Additionally, 3D printing can simulate surgical scenarios and enable the targeted training for doctors. This review aims to provide a summary of the latest developments in the clinical application of 3D printing in obstetrics.

Placenta accreta spectrum is a prevalent cause of severe postpartum hemorrhage and emergency hysterectomy.In recent years,there has been an increasing incidence of placenta accreta spectrum.Besides trau-matic uterine injury factors such as elevated cesarean section rates,other non-traumatic factors including uterine malformation,endometritis,uterine adenomyosis,in vitro fertilization-embryo transfer also warrant serious consid-eration.This article focuses on early disease detection,standardized diagnosis,prevention,and treatment of placental implantation disorders associated with non-traumatic factors to enhance the adverse outcomes for these parturients.

Objective To explore the technology frontiers for neuroblastoma treatment from the perspective of patent citation network. Methods Through patent analysis for neuroblastoma treatment, highly cited patents and highly cited papers in the citation network were taken as the research objects. The title and abstract of the citing patents were analyzed by text clustering to identify the technology frontiers. Through social network analysis, the core patents were identified from the indices of degree centrality, betweenness centrality, closeness centrality, and eigenvector centrality. Results A total of 6240 patent applications for neuroblastoma treatment were found, including 71304 patent citations and 88698 journal-article citations. Four technology frontiers were identified based on patent citation network, namely, drug target, drug design, tumor-indication expansion, and gene-expression regulation. Three technology frontiers were identified based on journal-article citation network. They were drug target, drug design, and tumor-indication expansion. Conclusion The development of technology for neuroblastoma treatment continues to be active. Drug target and drug design are the most important technology frontiers. This study could provide certain reference for neuroblastoma treatment from the perspective of information science.

Humans ; Infant, Newborn ; Neonatal Screening ; China

Objective:To investigate the safety of the Triple-P procedure in women complicated with severe placenta accreta spectrum disorders (PAS) and its influence on second pregnancy.Methods:From January 2015 to December 2017, the outcomes of the second pregnancy after the Triple-P procedure in 11 pregnant women complicated with PAS in the Third Affiliated Hospital of Guangzhou Medical University and the First Affiliated Hospital of Zhengzhou University were retrospectively analyzed.Results:By December 2021, a total of 11 pregnant women who underwent the Triple-P procedure for PAS had a second pregnancy, with a median interval of 3 years (2-3 years). Of the 11 pregnant women, 7 delivered after 36 weeks of gestation. The median gestational age was 38 weeks, and 4 terminated within the first trimester. PAS recurred in 1 of 7 pregnant women (1/7) and was associated with placenta previa. All of the 7 pregnant women were delivered by cesarean section, with a median postpartum blood loss of 300 ml (200-450 ml), and only one pregnant woman required blood transfusion. None of the pregnant women were transferred to the intensive care unit, and there were no uterine rupture, bladder injury, puerperal infection, and neonatal adverse outcomes.Conclusion:Pregnant women who underwent the Triple-P procedure for severe PAS could be considered for second pregnancy with strictly management by an experienced multidisciplinary team, which may result in a good outcome.